Evidence map›Paper›PMID 25532847›Full record

ArticleMolecules (Basel, Switzerland)2014

Design and optimisation of bioactive cyclic peptides: generation of a down-regulator of TNF secretion.

Roger New, Gurpal S Bansal, Malgorzata Dryjska, Michal Bogus, Patricia Green, Marc Feldmann, Fionula Brennan

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Binding Interactions of Peptide Aptamers.Molecules (Basel, Switzerland) · 2020
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Roger NewProxima Concepts Limited, c/o London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH, UK. rogernew@proximaconcepts.com.
Gurpal S BansalProxima Concepts Limited, c/o London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH, UK. gurpal8@sky.com.
Malgorzata DryjskaProxima Concepts Limited, c/o London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH, UK. gosia@herbatabakwitnaca.pl.
Michal BogusProxima Concepts Limited, c/o London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH, UK. michalbogus@proximaconcepts.com.
Patricia GreenKennedy Institute of Rheumatology, Roosevelt Drive, University of Oxford, Headington OX3 7FY, UK. patricia.green@kennedy.ox.ac.uk.
Marc FeldmannKennedy Institute of Rheumatology, Roosevelt Drive, University of Oxford, Headington OX3 7FY, UK. marc.feldmann@kennedy.ox.ac.uk.
Fionula BrennanKennedy Institute of Rheumatology, Roosevelt Drive, University of Oxford, Headington OX3 7FY, UK.
Adaptimmune (United Kingdom) · GBUniversity of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although strong binding interactions between protein receptor and ligand do not require the participation of a large number of amino acids in either site, short peptide chains are generally poor at recreating the types of protein-protein interactions which take place during cell recognition and signalling process, probably because their flexible backbones prevent the side chains from forming sufficiently rigid and stable epitopes, which can take part in binding with the desired strength and specificity. In a recently-reported study, it was shown that a proto-epitope containing F, R and S amino acids has the ability to down-regulate TNF secretion by macrophages. This paper extends these findings, putting those amino acids into a short cyclic peptide scaffold, and determining the optimal configuration required to overcome the problems of conformational instability, and give rise to molecules which have potential as therapeutic agents in human disease, such as rheumatoid arthritis.

Indexed as

AnimalsCell LineDown-RegulationDrug DesignImmunologic FactorsInterleukin-6LipopolysaccharidesMacrophagesMiceMicellesPeptides, CyclicTumor Necrosis Factor-alphaImmunologic FactorsInterleukin-6LipopolysaccharidesMicellesPeptides, CyclicTumor Necrosis Factor-alpha

Identifiers

PMID25532847
PMCPMC6271530
OpenAlexW2068398076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.